Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss
Jul 28 2025
•
By
Joseph Haas
Recognify will have to proceed without Atai if it takes inidascamine further in CIAS • Source: Shutterstock
More from Strategy
More from Business